Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | USP5 | P45974 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ABL2 | P42684 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200383 | 0.88 | DRD2 (0.66) | DRD2CHRM4SMN1; SMN2HTR2CUSP5 | |
| SCHEMBL7201323 | 0.86 | DRD2 (0.60) | DRD2CHRM4SMN1; SMN2HTR2CUSP5 | |
| SCHEMBL4950665 | 0.86 | DRD4 (0.63) | DRD2ABL1EGFRSRCABL2 | |
| SCHEMBL5947301 | 0.84 | DRD2 (0.61) | DRD2CHRM4SMN1; SMN2USP5CCR2 | |
| SCHEMBL26986820 | 0.84 | SLC18A3 (0.58) | DRD2SMN1; SMN2APPCCR5 | |
| SCHEMBL14067226 | 0.82 | DRD2 (0.72) | DRD2CHRM4HTR2CUSP5CCR2 | |
| SCHEMBL8350724 | 0.81 | DRD2 (0.79) | DRD2CHRM4HTR2C | |
| SCHEMBL20240320 | 0.80 | DRD2 (0.78) | DRD2CHRM4HTR2CNPY1R | |
| SCHEMBL7659138 | 0.80 | DRD2 (0.69) | DRD2CHRM4SMN1; SMN2HTR2CUSP5 | |
| SCHEMBL14590572 | 0.79 | QDPR (0.61) | DRD2CHRM4HTR2CUSP5CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | DRD2 3504/4885CHRM4 1265/4885SMN1; SMN2 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.